Martin S. Hirsch, MD

A. CAB-LA is less effective in the setting of active bacterial sexually transmitted infections

B. Every 2-month thigh injections of CAB-LA resulted in similar pharmacokinetics to every 2-month gluteal injections

C. During CAB-LA follow-up, the combination of a rapid HIV test and antigen/antibody test or 2 rapid tests that give the same result (eg, both positive or both negative) had high positive and negative predictive values

D. Integrase strand transfer inhibitor resistance mutations are unlikely to emerge in the setting of breakthrough infections with CAB-LA

Martin S. Hirsch, MD

Martin S. Hirsch, MD

Harvard Medical School

April 15, 2024: Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Preexposure Prophylaxis